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Abstract
Background: The role of vitamin E in breast cancer prevention and treatment has been widely investigated, and
the different tocopherols that comprise this nutrient have been shown to have divergent associations with cancer
outcome. Our previous studies have shown that α-Tocopherol-associated protein (TAP), a vitamin E binding protein,
may function as a tumor suppressor-like factor in breast carcinogenesis. The current study addresses the association
of TAP expression with breast cancer clinical outcomes.
Methods: Immunohistochemical stain for TAP was applied to a tissue microarray from a breast cancer cohort
consisting of 271 patients with a median follow-up time of 5.2 years. The expression of TAP in tumor cells was
compared with patient’s clinical outcome at 5 years after diagnosis. The potential role of TAP in predicting outcome
was also assessed in clinically relevant subsets of the cohort. In addition, we compared TAP expression and
Oncotype DX scores in an independent breast cancer cohort consisting of 71 cases.
Results: We demonstrate that the expression of TAP was differentially expressed within the breast cancer cohort,
and that ER+/PR ± tumors were more likely to exhibit TAP expression. TAP expression was associated with an
overall lower recurrence rate and a better 5-year survival rate. This association was primarily in patients with
ER+ tumors; exploratory analysis showed that this association was strongest in patients with node-positive tumors
and was independent of stage and treatment with chemotherapy. TAP expression in ER/PR negative or triple
negative tumors had no association with clinical outcome. In addition, we did not observe an association between
TAP expression and Oncotype DX recurrence score.
Conclusions: The significant positive association we found for α-Tocopherol-associated protein with outcome in
breast cancer may help to better define and explain studies addressing α-tocopherol’s association with cancer risk
and outcome. Additionally, further studies to validate and extend these findings may allow TAP to serve as a
breast-specific prognostic marker in breast cancer patients, especially in those patients with ER+ tumors.
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Table 1 Cohort characteristics. P value for difference between proportion of clinical characteristic within TAP positive and negative
patients determined with a two-proportion z-test, except for age and tumor size for which a t-test was employed
All cases TAP negative TAP positive
No. of patients % No. of patients % No. of patients % P value
Total 271 183 88
Grade
1 34 12.5 20 10.9 14 15.9 0.33
2 105 38.7 59 32.2 46 52.3 0.02
3 92 33.9 78 42.6 14 15.9 0.03
Unknown 40 14.8 26 14.2 14 15.9 nd
Stage
I 97 35.8 60 32.8 37 42 0.18
II 137 50.6 94 51.4 43 48.9 0.39
III 31 11.4 23 12.6 8 9.1 0.4
Unknown 6 2.2 6 3.3 0 nd
Age (avg, range)
58.1 (26–89) 56.9 (26–87) 62.6 (35–89) <0.001
T
T1 138 50.9 82 44.8 56 63.6 0.01
T2 101 37.3 74 40.4 27 30.7 0.19
T3 14 5.2 12 6.6 2 2.3 0.41
T4 8 3 6 3.3 2 2.3 0.47
Unknown 10 3.7 9 4.9 1 1.1 nd
N
N0 150 55.4 97 53 53 60.2 0.2
N1 108 39.9 74 40.4 34 38.6 0.43
N2 6 2.2 5 2.7 1 1.1 0.46
Unknown 7 2.6 7 3.8 0 nd
M
M0 258 99.2 172 98.9 86 100 1
M1 2 0.8 2 1.1 0 nd
Unknown 11 9 2 nd
Tumor size (avg, cm)
2.09 2.39 1.83 <0.001
Received chemotherapy
no 133 49.1 75 41 58 65.9 1
yes 130 48 101 55.2 29 33 1
Unknown 8 3 7 3.8 1 1.1 nd
ER
ER- 65 24 58 31.7 7 8 0.1
ER+ 197 72.7 120 65.6 77 87.5 0
Unknown 9 3.3 5 2.7 4 4.5 nd
HER2
HER2- 116 42.8 85 46.4 31 35.2 1
HER2+ 72 26.6 43 23.5 29 33 1
Unknown 83 30.6 55 30.1 28 31.8 nd
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Table 1 Cohort characteristics. P value for difference between proportion of clinical characteristic within TAP positive and negative
patients determined with a two-proportion z-test, except for age and tumor size for which a t-test was employed (Continued)
Hormone therapy
No 77 26.7 57 28.8 20 22.2 0.28
yes 187 64.9 120 60.6 67 74.4 0.03
Unknown 24 8.3 21 10.6 3 3.3 nd
Fig. 1 Invasive ductal carcinoma showing TAP staining positive (a), and negative with the positive internal control of normal/benign TDLU (b)
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Background
Breast cancer is the most common malignant tumor in
women worldwide, comprising 16 % of all female cancers.
Epidemiological studies have shown that vitamin E has a
potential utility in the prevention and treatment of human
malignancies, including breast cancer [1–3]. However
clinical trials on the effectiveness of dietary supplementa-
tion with vitamin E or α-tocopherol, the principle and
most active vitamin E isoform in human plasma, as an aid
in the prevention of cancer have not produced evidence of
a consistent association with decreased cancer occurrence
[4, 5]. The inconstancies between epidemiological studies
and intervention trials may be due to differing roles for
the tocopherols that comprise vitamin E or unexplained
genetic diversity in the study populations affecting how
they utilized vitamin E.
Our previous studies have shown that α-Tocopherol-as-
sociated protein (TAP), a vitamin E binding protein [6], is
selectively expressed in human breast, prostate, liver and
brain tissue and its expression can be evaluated by immu-
nohistochemical staining [7, 8]. We have shown that,
while TAP can facilitate vitamin E retention in cancer cells
and promote vitamin E-mediated anti-proliferation effects,
it can also act as a tumor suppressor-like protein in a vita-
min E-independent fashion. Overexpression of TAP in
prostate cancer cells was shown to suppress cell growth;
and a TAP siRNA knockdown in a prostate cell line led to
increased cell growth [7]. In human breast, we identified
that TAP is typically co-expressed with ER in sporadic
normal/benign luminal cells in terminal ductal lobular
units, and that TAP showed decreased expression in 57 %
of invasive breast carcinomas, including 46 % of ER and
PR positive carcinomas, and 80 % of high grade carcin-
omas [9]. Another study has shown that TAP mRNA level
is negatively associated with tumor stage and lymph node
status in breast cancer [10]. TAP expression therefore may
be a candidate for a marker of less aggressive breast
carcinoma.
Despite the advances in multidisciplinary treatment,
breast cancer remains the second most common cause
of death related to cancer in women. In addition to the
routine pathologic characteristics of breast cancer, such
as tumor size, grade, vascular invasion, lymph node me-
tastasis, ER/PR/Her2 status etc., genes which may have
an association with tumor biology and help in predicting
recurrence, therapeutic response and survival have been
studied widely. Currently there are at least nine gene ex-
pression signatures showing some correlation with cer-
tain clinical breast cancer outcomes [11–16]. The genes
included in these panels are diverse but largely related to
cell cycle regulation and proliferation, the ER pathway,
and to a lesser degree, the immune system. Although
these gene panels have similar outcomes performance,
they exhibit a large degree of discordance in the
assignment of a particular breast tumor to a specific
prognostic group [11]. More accurate prognostic pre-
dictive gene signatures will depend on better under-
standing of the genes specifically involved in breast
cancer carcinogenesis.
To further investigate if TAP expression is associated
with clinical outcome in breast carcinomas, we studied
TAP expression in a breast cancer cohort of 271 patients
diagnosed with invasive breast carcinomas with median
follow up time of 5.2 years. In addition, in an independ-
ent cohort of 71 breast cancer cases, we compared TAP
expression with the Oncotype DX recurrence score to
determine if there was a correlation between TAP ex-
pression and this clinically available multigene prognos-
tic/predictive assay.
Methods
A tissue micro-array comprising 288 patient samples from
a primary invasive breast cancer cohort from the
Clearview Cancer Institute (CCI, AL, U.S.A.), consisting of
all available patient samples collected from 1990 to 2001,
was constructed. The patient average age was 58.9 (range
26–89), with an average tumor size 2.21 cm (range 0.2–8.0)
and a median follow up time of 5.2 years. Ninety eight tu-
mors were stage 1, 141 stage 2, and 33 stage 3. One hun-
dred fifty four patients had negative lymph nodes, while
118 patients had positive lymph node(s). One hundred
thirty two patients had received chemotherapy plus hormo-
nal therapy, while 156 were untreated or treated with hor-
monal therapy only. No patients had been treated with
Herceptin. Thirty six tumors were grade 1, 106 were grade
2 and 93 were grade 3. Within this cohort, 271 patients had
complete follow-up and TAP expression data. The compos-
ition of this set of patients is as shown in Table 1.
An independent cohort of 71 invasive breast carcin-
omas for which Oncotype DX (Genomic Health, Inc.)
recurrence scores had been determined were identified
from the files of the Department of Pathology and
Laboratory Medicine at Strong Memorial Hospital
(Rochester, NY). All cases were hormone receptor posi-
tive, Her2 negative, and lymph node negative. A repre-
sentative whole tissue section was cut from each tumor.
Table 2 TAP and hormone receptor status, patient counts.
P value for difference between proportion of TAP positive and
negative patients determined with a two-proportion z-test
TAP- TAP+ P value
Hormone Receptor Negative (ER & PR-) 48 6 <0.001
ER- 58 7 <0.001
Hormone Receptor Positive (ER or PR+) 127 78 <0.001
ER+ 120 77 0.001
HR positive/ HER2- 56 29 0.003
HR positive/ HER2+ 31 28 0.35
Wang et al. BMC Clinical Pathology    Page 4 of 10
This study was approved by the Huntsville Hospital
Institutional Review Committee. Archived tumor sam-
ples were provided by the Clearview Cancer Institute of
Huntsville Alabama and corresponding anonymized pa-
tient data was provided via an institutional review
board–approved database. An IRB exemption for the use
of the tissue samples was granted by the Huntsville
Hospital Institutional Review Committee as all patient
data were a) anonymized, b) consent was unnecessary,
and c) only excess tissue was used.
Tissue arrays were processed as previously described
[17]. TAP antibody was generated in house as previously
published. Immunohistochemical staining for TAP was
performed on tissue micro-array and whole tissue sec-
tions with the method we described previously [8]. TAP
expression was classified as positive or negative, with
positive expression defined as any cytoplasmic and/or
nuclear staining (Fig. 1). Commercial antibodies for ER,
PR, and HER2 were stained by a commercial service (US
Labs Inc). ER and PR were considered positive if at least
Fig. 2 Patients with TAP-positive tumors had a lower 5-year recurrence rate (a) and better 5-year survival rate (b) than the patients with TAP-negative
tumors. TAP-positive tumors are shown via a dotted line, TAP-negative tumors via a solid line
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1 % of the cells examined exhibited any nuclear staining,
and HER2 was scored positive when intense membrane
staining in more than 10 % of invasive tumor cells was
observed.
In assessing association with outcome, the likelihood
ratio test was used in univariate analyses, and the Wald
test for multivariate models. All p values are presented
as two sided, with a value of less than 0.05 being consid-
ered significant.
Results
In the CCI breast cohort of 271 breast carcinoma samples,
we observed positive TAP staining in 88 (32 %) and nega-
tive staining in 183 (68 %) tumors. Consistent with our
previous findings, we found that ER+/PR ± tumors are
more likely to exhibit TAP expression than hormone nega-
tive tumors (Table 2). Overall, patients with TAP-positive
tumors had a lower 5-year recurrence rate (N = 271, p =
0.002) and better 5-year survival rate (N = 264, p = 0.010)
(Fig. 2a, b). This positive association with outcome was
conserved in all ER-positive tumors, regardless of PR sta-
tus (5 year recurrence, HR = 0.35, p = 0.02, 5 year survival,
HR = 0.141, p = 0.014) (Fig. 3a, b). This association was
also significant at 10 years post diagnosis (10 year
survival HR = 0.21, p = 0.0024; 10 year recurrence HR =
0.55, p = 0.023). Looking further at the clinically relevant
ER+/PR±/Her2- patients, significant associations were
also observed (5 year recurrence, HR = 0.17, p = 0.035,
5 year survival, HR = <0.001, p = 0.007, N = 81). TAP was
not prognostic of 5 year recurrence in ER+/HER2+ cases
(HR = 0.38 p = 0.22, N = 57), ER-/HER2-(HR < 0.01, p =
0.23, N = 32), or ER-/HER2+ cases (HR = 4.1 p = 0.28, N =
15). Tumors negative for ER and PR had a non-significant
association with 5-year recurrence and survival (Fig. 3c,
d). In triple negative patients the association remained
non-significant, though low patient numbers (N = 25)
makes it difficult to draw conclusions from this subset
analysis. Exploratory analysis showed that the association
with outcome was even stronger in node-positive patients
(5-year recurrence: N = 118, p = 0.0001; 5-year survival:
N = 114, p = 0.0036), but it was not significant in node-
negative patients (5-year recurrence: N = 151 and p = 0.98;
5-year survival: N = 150 and p = 0.72) (Fig. 4a-d). Within
PR subsets (ER+/PR- and ER+/PR+), TAP did not have a
significant association with recurrence (p = 0.102 and
0.098, respectively), though the hazard ratio remained low.
Fig. 3 In patients with ER+/PR ± positive tumors, TAP positivity was associated with a better 5 year recurrence (a) and survival (b). In patients with
hormone negative (ER-/PR-) tumors TAP showed a non-significant negative association with 5 year recurrence (c) and survival (d)
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Furthermore, TAP was independent of PR when assessed
as a multivariable model (data not shown).
In an exploratory multivariate analysis of TAP status
and common clinical variables, TAP was independent of
age, stage, hormonal therapy and chemotherapy status
with 5 year recurrence as the outcome measurement in all
patients (Table 3). TAP was not independent of grade,
which suggests that grade and TAP were measuring a
shared aspect of cell biology. Indeed, there was a signifi-
cant negative association between grade and TAP (p <
0.0001 via chi-square). TAP positive tumors were more
likely to represent low grade tumors compared to TAP
negative tumors. In patients with ER+/PR ± tumors, TAP
expression was independent of stage and age in predicting
5 year recurrence; while in patients with ER+/PR±/Her2-
tumors, TAP was not independent of stage (5 year recur-
rence HR = 0.18, p = 0.110). However, only 81 patients
were included in this subset. When looking at 5 year sur-
vival, TAP expression was independent of age and stage,
but not chemotherapy status or tumor grade.
In the study of tumors with a known Oncotype DX re-
currence score, TAP was positive in 47 of the 71 tumors
(66.2 %), with 29 of 43 (67.4 %) in a low risk group, 16
of 24 (66.7 %) in an intermediate risk group, and 2 of 4
(50 %) in a high risk group (Table 4). There was no asso-
ciation observed between TAP expression and Oncotype
DX recurrence risk using a Fisher’s exact test (P = 0.60).
The limitation of the study includes relatively small
sample size in the CCI breast cohort and Oncotype DX
cohort. Ki67 labeling index data and the status of vascu-
lar invasion were not available for analysis.
Discussion
Genes involved in cell proliferation have been shown to
comprise a major component of many of the available
gene expression signatures used to predict clinical out-
come in breast cancer patients [11–16]. TAP has also
been implicated in the control of cellular proliferation
and other aspects of tumor growth. Researchers demon-
strated that vitamin E derivatives can inhibit cell prolif-
eration and colony formation of breast cancer cell lines,
and induce apoptosis of the tumor cells [18–21]. As a
vitamin E binding protein, TAP can promote vitamin E
retention and thus increase its concentration in cells.
Our previous studies have demonstrated that TAP can
promote vitamin E-induced inhibition of tumor cell
Fig. 4 The association between TAP expression and better prognosis was even stronger in node-positive patients in 5 year recurrence (a) and
survival (b), but was not significant in node-negative patients in 5 year recurrence (c) or survival (d)
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proliferation and also regulate tumor cell growth in a
vitamin E-independent fashion [7]. We also showed that
TAP is selectively expressed in normal/benign breast lu-
minal epithelium, but not in many other organ systems
[8]. TAP expression is down-regulated at the mRNA and
protein levels in several human breast cancer cell lines
and in human breast carcinomas compared to a nonma-
lignant cell line and to normal/benign breast tissue. We
extended these observations in current study, which
showed that TAP expression is associated with an overall
more favorable outcome, both in terms of tumor recur-
rence and survival rate in breast cancer patients. These
findings, taken together, suggest that TAP is a regulator
of cell proliferation that can affect breast carcinogenesis
and tumor prognosis.
Breast cancer is a heterogeneous group of diseases.
The biological features and clinical behavior of individ-
ual tumors are frequently different, even within the mor-
phologically low grade, ER+/PR+/Her2- subtype, which
is generally considered to be a group with a better prog-
nosis. It is important to identify novel markers which
can predict clinical outcomes in this group. We have re-
ported that TAP is co-expressed with ER in the normal/
benign breast luminal epithelium of terminal ductal
lobular units, where breast carcinogenesis is most likely
to be initiated, and that TAP is down regulated in 46 %
of ER and PR positive breast carcinomas, indicating that
the loss of TAP expression may be associated with the
process of hormonal carcinogenesis [9]. Here we have
demonstrated that TAP expression in ER+/PR±/Her2-
tumors is associated with a significantly better 5-year re-
currence free and survival rate. This finding could be
clinically significant in terms of further predicting tumor
Table 3 Association of TAP and other clinical variables with outcome using Cox proportional hazard regression. TAP, chemotherapy,
grade, stage and age are shown as individual and multivariable models. Variables with a significant association with survival or
recurrence are shown in bold
5 year survival 5 year recurrence 5 year recurrence, ER+/PR±
HR p N HR p N HR p N
TAP 0.26 (0.08, 0.87) 0.01 264 0.35 (0.16, 0.74) 0.002 271 0.35 (0.13, 0.92) 0.02 197
Hormone therapy 0.54 (0.25, 1.2) 0.12 262 0.68 (0.38, 1.2) 0.21 261 1.8 (0.55, 6.2) 0.28 192
Chemotherapy 4.34 (1.63, 11.6) 0.001 262 2.51 (1.37, 4.6) 0.002 263 2.2 (1, 4.84) 0.05 193
Grade 4.44 (1.74, 11.3) <0.001 230 2.3 (1.34, 3.93) 0.001 231 2.5 (1.24, 5.05) 0.007 175
Stage 3.35 (1.82, 6.16) <0.001 264 2.71 (1.76, 4.17) <0.001 265 2.66 (1.47, 4.83) 0.001 195
Age 0.98 (0.95, 1.01) 0.193 264 0.98 (0.97, 1) 0.054 265 0.97 (0.94, 1) 0.058 195
TAP 0.28 (0.08, 0.95) 0.04 264 0.38 (0.18, 0.81) 0.012 265 0.37 (0.14, 0.98) 0.045 195
Stage 3.25 (1.76, 6) <0.001 2.63 (1.71, 4.06) <0.001 2.57 (1.41, 4.69) 0.002
TAP 0.55 (0.16, 1.93) 0.35 230 0.54 (0.23, 1.24) 0.15 231 0.51 (0.19, 1.39) 0.19 174
Grade 3.93 (1.52, 10.18) 0.005 2.05 (1.19, 3.52) 0.01 2.3 (1.15, 4.59) 0.018
TAP 0.28 (0.08, 0.94) 0.039 264 0.38 (0.18, 0.82) 0.014 265 0.37 (0.14, 0.98) 0.045 195
Age 0.99 (0.96, 1.02) 0.37 0.98 (0.96, 1.01) 0.16 0.97 (0.94, 1.01) 0.097
TAP 0.27 (0.08, 0.90) 0.032 262 0.37 (0.17, 0.78) 0.0093 261 0.35 (0.13,0.93) 0.036 192
Hormone therapy 0.58 (0.27, 1.3) 0.17 0.73 (0.41, 1.3) 0.3 1.77 (0.53, 5.9) 0.35
TAP 0.34 (0.1, 1.14) 0.081 262 0.42 (0.2, 0.91) 0.027 263 0.38 (0.14, 1.01) 0.052 193
Chemotherapy 3.69 (1.37, 9.92) 0.01 2.16 (1.17, 4.01) 0.014 1.94 (0.87, 4.3) 0.1
TAP 0.33 (0.1, 1.13) 0.078 262 0.41 (0.19, 0.89) 0.023 263 0.38 (0.14, 1.03) 0.057 193
Stage 2.77 (1.42, 5.4) 0.003 2.44 (1.53, 3.9) 0 2.42 (1.27, 4.61) 0.007
Chemotherapy 2.21 (0.79, 6.17) 0.13 1.35 (0.7, 2.59) 0.37 1.23 (0.53, 2.85) 0.63
TAP 0.32 (0.1, 1.1) 0.07 262 0.41 (0.19, 0.89) 0.024 263 0.39 (0.15, 1.06) 0.065 193
Stage 2.8 (1.43, 5.47) 0.003 2.44 (1.53, 3.9) 0 2.53 (1.34, 4.76) 0.004
Chemotherapy 2.98 (0.89, 10) 0.077 1.34 (0.61, 2.94) 0.47 0.85 (0.31, 2.32) 0.75
Age 1.02 (0.98, 1.06) 0.35 1 (0.97, 1.03) 0.98 0.97 (0.94, 1.01) 0.19
Table 4 Comparison of TAP positivity and OncoTypeDx
Recurrence scores
Recurrence Score TAP + TAP - Total
1 29 14 43
2 16 8 24
3 2 2 4
Total 47 24 71
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behaviors of ER+/PR±/Her2- subtype breast carcinomas.
Currently, there are few breast carcinogenesis-related
oncogenes and tumor suppressor genes that are impli-
cated in the clinical treatment and prognosis. Her2 and
p53, the most widely evaluated cancer-related genes, are
only altered in approximately 20-25 % of breast carcin-
omas, primarily in ER/PR negative tumors [22]. In con-
trast, TAP is altered in 57 % of breast carcinomas,
including 46 % ER/PR+ tumors, thus may serve as a use-
ful complement to existing biomarkers.
OncotypeDX has been used to guide clinical approaches
for ER-positive, lymph node-negative breast cancer pa-
tients. Even though TAP expression is associated with bet-
ter clinical outcome in ER-positive tumors, we did not
identify any association between TAP expression and
OncotypeDX recurrence scores in the additional cohort.
This may suggest that TAP expression is associated with a
different aspect(s) of tumor biology than is OncotypeDX
and may be a useful complement in predicting patient
outcome and tumor subclassification. Further study with a
larger population of ER+ tumors is needed to help validate
these findings.
Several studies have demonstrated a protective effect of
vitamin E on the occurrence of several cancers (for review
see [3]). However clinical trials have found little support
for dietary supplementation [23]. The disparity of these re-
sults could be due to vitamin E not being cancer prevent-
ive at the supra-nutritional level, significant roles for other
vitamin E isoforms, such as γ- and δ-tocopherols [24], or
genetic diversity among dietary intervention trial partici-
pants contributing to unrecognized heterogeneity in how
they utilized vitamin E. Our study found considerable het-
erogeneity among the tumors in expression of TAP, the
vitamin E binding protein, and its significant association
with cancer progression. This finding suggests a possible
role for TAP in the interplay between vitamin E and can-
cer progression. Stratification of trial participation by TAP
expression may be an interesting and important aspect for
the elucidation of how dietary vitamin E supplementation
may affect cancer risk and prognosis.
Conclusions
In summary, we demonstrated that TAP, as a proliferation-
related gene in breast carcinogenesis, is associated with a
better 5-year clinical outcome, particularly in node-positive
and ER+ breast cancer patients. TAP may serve as a prog-
nostic marker, especially in those patients with ER+ low
grade breast cancers, and may also serve to stratify studies
assessing the role and utility of vitamin E or α-tocopherol
supplementation for the prevention of cancer.
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